The present study examined and compared the spasmolytic effects of 3 harmala alkaloids, harmine, harman, and harmaline, on carbachol-, histamine-, and KCl-induced contractions of guinea-pig isolated tracheal preparations. All 3 compounds relaxed the tracheal preparations contracted by these spasmogens with similar or different EC 50 values, harmine being the most potent one. The cumulative concentration-response curves of all 3 compounds for carbacholinduced contraction were shifted to the right by propranolol (1 mM) pretreatment, indicating the involvement of the activation on the b-adrenoceptors. All 3 compounds shifted the concentration-response curves of carbachol to the right in a parallel manner with the pA 2 values comparable with their relaxation EC 50 values, indicating a competitive antagonism at the muscarinic receptors. Receptor binding assays indicated that all 3 compounds interacted with lung muscarinic receptors (K i Ω11-13 mM), histamine H 1 receptors (K i Ω27-107 mM), and b 2 -adrenoceptors (K i Ω20-51 mM). Therefore, in addition to their actions on receptor-linked and voltage-dependent Ca 2π channels as reported in other types of smooth muscle, the present study suggests that the actions on muscarinic receptors, histamine H 1 receptors, and b 2 -adrenoceptors are also involved in their spasmolytic effects on airway smooth muscles.The harmala alkaloids harmine, harman, harmaline, and harmalol are the psychological active principles from the seeds of Peganum harmala L., which are also found widely in other medicinal plants. Harman is also found endogenously in mammalian tissues (Airaksinen & Kari 1981;Rommelspacher et al. 1991). These harmala alkaloids have a wide spectrum of pharmacological actions in the central nervous system such as tremorogenesis (Poirier et al. 1966;Lutes et al. 1988), hypothermia (Bruinvels & Sourkes 1968), hallucinogenesis (Zetler et al. 1974;Grella et al. 1998), central monoamine oxidase inhibition (Nelson et al. 1979;Fuller et al. 1986;May et al. 1991), convulsive or anticonvulsive actions (Loew et al. 1985) and binding to various receptors including 5-HT receptors and the benzodiazepine binding site of GABA A receptors (Lamarre & Puil 1974;Rommelspacher et al. 1980 Rommelspacher et al. & 1985. In addition, these compounds also have antioxidative (Tse et al. 1991), platelet aggregation inhibitory (Saeed et al. 1993), and immunomodulatory effects (Li 1996). There are also some reports concerning the cardiovascular actions of these harmala alkaloids. For example, it has been reported that harmine reduces systemic arterial blood pressure and total peripheral vascular resistance; harmaline-evoked decreases are frequently followed by a secondary increase; and the effects of harmalol on these two parameters are inconsistent (Aarons et al. 1977). Recently, we reported in vivo cardiovascular effect and in vitro vasorelaxant effect of harman (Shi et al. 2000) and in vitro vasorelaxant effects of harmine, harmaline, and harmalol (Shi et al. 2001). Our results suggest...